Toronto, Canada, September 4, 2016 – Verity Pharmaceuticals Inc., (“Verity” or the “Company”) a specialty pharmaceutical company announced today the election of Drs. Jack Barkin, Neil Fleshner, Sender Herschorn, Robert Devenyi and David Dunne to its Scientific Advisory Board (“SAB”). The SAB is expected to serve as a strategic network of scientific and clinical experts to Verity. The SAB is expected to be an integral part of the Company’s strategy as it continues to assess opportunities to expand its pipeline; validate corporate medical marketing initiatives; and advise on market trends, medical commercial issues and clinical trial awareness.
“We are honored to be able to access the academic and health science business expertise of these global level Key Opinion Leaders” Said Verity Chief Executive Officer, Howard Glase.
The SAB is chaired by, Dr. Jack Barkin a co-founder in the Company. The members of Verity’s SAB are:
Dr. Jack Barkin, MD, FICS, FACS, DABU, MHM, CCPE, FRCS Dr. Barkin is Chief of Staff at Humber River Hospital, Past Chief of Urology at that institution as well as the previous Director of surgery and Surgical Oncology. He is also an Associate Professor of Urology at the University of Toronto and an Adjunct Clinical Professor, Department of Surgery at the University of Toronto. Dr. Barkin has been an active participant in clinical research for over 25 years; he has also lectured around the world. His expertise in the medical field of urology leads him to be an incredible asset to the Verity Pharma team.
Dr. Neil Fleshner, MD, MPH, FRECSC
Dr. Neil Fleshner is the Martin Barkin Professor and Chairman of Urology at the University of Toronto. Aside from surgical practice, Dr. Fleshner conducts research on urologic cancer prevention with an emphasis on prostate cancer. Dr. Fleshner is certified in both urology and epidemiology. His responsibilities include maintaining academic relations, product review and selection, regulatory stewardship and maintaining relations with key opinion leaders.
Dr. Sander Herschorn, BSc, MDCM, FRCSC
Dr. Herschorn is Professor in the Division of Urology at the University of Toronto and attending Urologist at Sunnybrook Health Sciences Centre. Dr. Herschorn has produced many scientific publications, and he is an Editorial Board Member of Canadian Urological Association Journal and Neurourology and Urodynamics. As a highly decorated doctor, his experience and insight is vital in guiding the decisions made by the Verity Executives.
Dr. Robert Devenyi, MD, MBA, FRCSC, FACS
Dr. Devenyi is a vitreoretinal surgeon and Professor of Ophthalmology and Vision Sciences at the University of Toronto. He is Ophthalmologist-in-chief and Direct of Retinal Services at the University Health Network (UHN), which is affiliated with the University of Toronto. Dr. Devenyi is a global key opinion leader and a true asset to the Verity Pharma team.
Dr. David Dunne, PhD, B.Comm
Dr. Dunne is a Professor and Director of the MBA Program at the University of Victoria. His expertise lies in branding, creative problem solving, international marketing and strategic management. He is the recipient of numerous teaching awards including the President’s National Teaching Award, and Canada’s most prestigious award, the 3M National Teaching Fellowship. Along his teaching career, Dr. Dunne has served as a consultant to numerous multinational pharmaceutical organizations.
Chief Executive Officer
About Verity Pharmaceuticals Inc.
Verity Pharmaceuticals Inc. is a Canadian owned and operated specialty pharmaceutical company, dedicated to providing access to pharmaceutical products which have been withdrawn from the Canadian market or are in short-drug supply. Verity is currently in negotiations to secure eight (8) in-licensing agreements. By working with innovative international pharmaceutical organizations, as well as a highly qualified team of physicians, executives and investors, Verity Pharmaceuticals aims to ensure a predictable high-quality supply of products for the Canadian market.
Some of the statements made constitute forward-looking statements as per the Ontario Securities Commission. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance and achievements of Verity Pharmaceuticals Inc. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements are often, but not always, identified by words such as ‘believes’, ‘may’, ‘likely’, ‘plans’ or similar words.